American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.